Nasdaq:US$9.56 (+0.50) | HKEX:HK$15.34 (+0.18) | AIM:£1.50 (+0.01)
搜索
新聞檔案

通過選擇所需的新聞類型，可以獲得最新的公告或演示文稿。

請使用 「新聞主題」進一步挑選公告類別。

所有公告的全文可以PDF文件的形式下載。 為方便起見，某些公告的部分或全部文字內容以網頁的方式呈現。 如存有任何不一致之處，請以PDF版本為準。

新聞類型
公告及新聞稿
演示文稿
新聞主題
其他業務
監管通知
腫瘤學 / 免疫學
集團
12345
6
7891011121314
找到相關結果： 689
公告及新聞稿, 監管通知 | 2018-11-30

Total Voting Rights
London: Friday, November 30, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2018, the issued share capital of Chi-Med consisted of 66,623,441 ordinary shares of US$1.00 each
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2018-11-29

和黃醫藥就評估索凡替尼和呋喹替尼 與PD-1檢查點抑製劑的聯合療法簽訂多項合作協議
2018年11月29日，星期四：和黃中國醫藥科技有限公司（簡稱「和黃醫藥」或「Chi-Med」）（納斯達克/倫敦證交所：HCM）簽訂了4項合作協議，對和黃醫藥的索凡替尼（surufatinib, 亦稱HMPL-012或sulfa
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2018-11-26

和黃醫藥宣布呋喹替尼膠囊（愛優特®）首次商業上市
2018年11月26日，星期一：和黃中國醫藥科技有限公司（簡稱「和黃醫藥」或「Chi-Med」）（納斯達克/倫敦證交所：HCM）今日宣布呋喹替尼膠囊（愛優特®）首次商業上市，並在中國開始產品銷
閱讀更多
下載新聞稿 (PDF)
腫瘤學 / 免疫學 | 2018-11-20

Chi-Med Receives BayHelix R&D Achievement of the Year Award at BioCentury China Healthcare Summit
Shanghai: November 20, 2018: Hutchison China MediTech (“Chi-Med”) received “R&D Achievement of the Year” Award from BayHelix at the BioCentury China Healthcare Summit on November 14, 2018. Hutchison MediPharma, the Innovation Platform
閱讀更多
公告及新聞稿, 腫瘤學 / 免疫學 | 2018-11-16

和黃醫藥公佈呋喹替尼在中國以三線晚期非小細胞肺癌為適應症的 III期臨床試驗FALUCA研究結果
- 研究沒有達到總生存期的主要終點，但呋喹替尼組患者無進展生存期得到延長 -   2018年11月16日，週五：和黃中國醫藥科技有限公司（簡稱「和黃醫藥」或「Chi-Med」）（納斯達克/倫敦
閱讀更多
下載通告 (PDF)
公告及新聞稿, 監管通知 | 2018-10-31

Total Voting Rights
London: Wednesday, October 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at October 31, 2018, the issued share capital of Chi-Med consisted of 66,618,660 ordinary shares of US$1.00 eac
閱讀更多
公告及新聞稿, 監管通知 | 2018-10-22

Grant of Share Options under Share Option Scheme
London: Monday, October 22, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on October 19, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Mee
閱讀更多
公告及新聞稿, 腫瘤學 / 免疫學 | 2018-10-18

Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China
London: Thursday, October 18, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in combination with azacitidine, an approved nuc
閱讀更多
公告及新聞稿, 監管通知 | 2018-10-05

Appointment of HSBC Bank plc as Joint Corporate Broker in London
London: Friday, October 5, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has appointed HSBC Bank plc as its joint Corporate Broker in London with immediate effect. Panmure Gordon (UK) Limited will co
閱讀更多
公告及新聞稿, 腫瘤學 / 免疫學 | 2018-09-05

和黄医药宣布呋喹替尼胶囊在中国获批 用于治疗既往接受过其他治疗的结直肠癌患者
-呋喹替尼膠囊為轉移性結直腸癌患者提供了新的口服治療選擇，將在中國市場以商品名愛優特®進行銷售-   -已在JAMA發表的研究數據表明，和安慰劑相比愛優特®能夠使患者總生存期得到
閱讀更多
下載通告 (PDF)
公告及新聞稿, 監管通知 | 2018-08-31

Total Voting Rights
London: Friday, August 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 31, 2018, the issued share capital of Chi-Med consisted of 66,535,683 ordinary shares of US$1.00 each, wi
閱讀更多
公告及新聞稿, 監管通知 | 2018-08-07

Grant of Share Options under Share Option Scheme
London: Tuesday, August 7, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on August 6, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meetin
閱讀更多
公告及新聞稿, 集團 | 2018-07-27

Chi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical Programs
London: Friday, July 27, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2018 and updates shareholders on key clinical programs. Fruquinti
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2018-07-23

和黃醫藥在美國啟動索凡替尼以胰腺神經內分泌瘤和膽管癌為適應症的Ib/II期概念驗證臨床試驗
2018年7月23日：和黃中國醫藥科技（簡稱「和黃醫藥」或「Chi-Med」）（納斯達克/倫敦證交所：HCM）今日宣佈在美國啟動索凡替尼以胰腺神經內分泌瘤（NET）和膽管癌（BTC）為適應症的Ib/II期
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 監管通知 | 2018-06-29

Total Voting Rights
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at June 29, 2018, the issued share capital of Chi-Med consisted of 66,532,683 ordinary shares of US$1.00 each, with e
閱讀更多
公告及新聞稿, 監管通知 | 2018-06-29

Blocklisting Six Monthly Return
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: (a)
閱讀更多
公告及新聞稿, 新聞稿, 集團 | 2018-06-29

Chi-Med to Announce 2018 Half-Year Financial Results
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2018 on Friday, July 27, 2018 at 7:00 am British Summer Time (BST). An analy
閱讀更多
演示文稿, 科學出版物 | 2018-06-26

JAMA: Fruquintinib vs Placebo in Previously Treated Metastatic Colorectal Cancer
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial Jin Li; Shukui Qin; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Lei Yang; Yanhong Deng;
閱讀更多
公告及新聞稿, 監管通知 | 2018-06-07

Grant of Share Options under Share Option Scheme
London: Thursday, June 7, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on June 6, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting i
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2018-06-04

和黃醫藥在2018年ASCO年會上公佈呋喹替尼FRESCO研究更多研究數據
-繼2017年ASCO年會上就FRESCO研究達到全部研究終點，呋喹替尼安全性良好，較其他靶向療法脫靶毒性更低等數據進行口頭報告後，和黃醫藥在2018年ASCO年會上公佈了FRESCO研究進一步的研究數據-
閱讀更多
下載新聞稿 (PDF)
演示文稿, 科學出版物 | 2018-06-04

ASCO 2018: Colorectal cancer Q-TWiST with fruquintinib treatment in FRESCO
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer treated with fruquintinib in FRESCO Presenter: Yu-Xian Bai Other Authors: Hongyan Li, Ning Wang, Xiaojun Guo, Wei Wang, Songhua F
閱讀更多
View Poster
演示文稿, 科學出版物 | 2018-06-04

ASCO 2018: Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO
Presenter:     Ruihua Xu Other Authors: Jin Li, Yu-Xian Bai, Yanhong Deng, Lei Yang, Haijun Zhong, Zhendong Chen, Hongming Pan, Weijian Guo, Yongqian Shu, Ying Yuan, Jianming Xu, Lin Shen, Ning Wang, Xin Wang, Haidong Chi, Jack Peng, Y
閱讀更多
公告及新聞稿, 監管通知 | 2018-05-31

Total Voting Rights
London: Thursday, May 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at May 31, 2018, the issued share capital of Chi-Med consisted of 66,515,756 ordinary shares of US$1.00 each, with e
閱讀更多
公告及新聞稿, 新聞稿, 集團 | 2018-05-11

Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference
Press Release   London: Friday, May 11, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today that Christian Hogg, Chief Executive Officer, will present at the Bank of America Merrill Lynch 2018 Health Care Confe
閱讀更多
公告及新聞稿, 監管通知 | 2018-04-30

Total Voting Rights
London: Monday, April 30, 2018: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 30, 2018, the issued share capital of Chi-Med consisted of 66,484,620 ordinary sh
閱讀更多
公告及新聞稿, 監管通知 | 2018-04-27

Results of AGM Meeting
London: Friday, April 27, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 27, 2018 were duly pa
閱讀更多
公告及新聞稿, 監管通知 | 2018-04-23

Block Admission
London: Monday, April 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that an application has been made to the London Stock Exchange plc for a block admission of 1,425,597 ordinary shares, par value of US$
閱讀更多
公告及新聞稿, 監管通知 | 2018-04-23

Grant of Share Options under Share Option Scheme
London: Monday, April 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on April 20, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting
閱讀更多
演示文稿, 科學出版物 | 2018-04-17

AACR 2018: MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib
4541 / 26 - MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor Presenter/Authors M. M. Frigault1, S. Signoretti2, A. Markovets
閱讀更多
View Poster
公告及新聞稿, 監管通知 | 2018-03-29

Total Voting Rights
London: Thursday, March 29, 2018: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 29, 2018, the issued share capital of Chi-Med consisted of 66,476,279 ordinary
閱讀更多
公告及新聞稿, 監管通知 | 2018-03-28

Vesting of awards under the Long Term Incentive Plan
London: Wednesday, March 28, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that following the publication of the 2017 annual report of Chi-Med on March 26, 2018, the following awards granted under the Long Term In
閱讀更多
公告及新聞稿, 集團 | 2018-03-26

2017 Annual Report and Notice of Annual General Meeting
London: Monday, March 26, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2017 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders.
閱讀更多
演示文稿, 科學出版物 | 2018-03-23

ASCPT 2018: Fruquintinib Pharmacokinetics in Humans
Pharmacokinetics of Fruquintinib in Humans Venue: American Society for Clinical Pharmacology & Therapeutics Annual Meeting in Orlando, Florida, USA Abstract #: PII-116 Authors: Ke Li, Chen Yu, Yanmei Liu, Xiangkun Li, Sumei Xia, Jian Wa
閱讀更多
公告及新聞稿, 監管通知 | 2018-03-21

Director’s Share Dealing
London: Wednesday, March 21, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Graeme Jack, Independent Non-executive Director, purchased a total of 3,000 American Depositary Shar
閱讀更多
公告及新聞稿, 監管通知 | 2018-03-20

Grant of Share Options under Share Option Scheme
London: Tuesday, March 20, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 19, 2018, it granted share options under the Share Option Scheme adopted by Chi-Med at its Annual General Meeting on April 24,
閱讀更多
公告及新聞稿, 監管通知 | 2018-03-19

Director's Share Dealing
London: Monday, March 19, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Dr Dan Eldar, Non-executive Director, purchased a total of 2,768 American Depositary Shares of the Company (“ADSs”,
閱讀更多
公告及新聞稿, 集團 | 2018-03-12

Publication of Form 20-F for the Year Ended December 31, 2017
公告及新聞稿, 集團 | 2018-03-12

Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs
Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs Group: Year of major progress; results in line with guidance Group revenue up 12% to $
閱讀更多
演示文稿, 科學出版物 | 2018-03-12

Journal of Clinical Oncology: Phase II Trial of Fruquintinib in Patients with Advanced Nonsquamous NSCLC
 Shun Lu, Jianhua Chang, Xiaoqing Liu, Jianhua Shi, You Lu, Wei Li, Jin-ji Yang, Jianying Zhou, Jie Wang, Tongtong An, Lei Yang, Zhe Liu, Xiangdong Zhou, Mo Chen, Ye Hua and Weiguo Su Abstract Purpose Patients with advanced non‒small-cell lung
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2018-03-06

和黄医药在中国启动依吡替尼以胶质母细胞瘤为适应症的Ib/II期概念验证临床试验
2018年3月6日: 和黃醫藥今日宣佈在中國啟動依吡替尼Ib/II期概念驗證臨床試驗，目標受試者為表皮生長因子受體（EGFR）基因擴增的膠質母細胞瘤患者。膠質母細胞瘤是腦腫瘤的一種主要類型
閱讀更多
下載新聞稿 (PDF)
演示文稿, 科學出版物 | 2018-02-24

ACOS 2018: Adverse Events of Special Interest Profiles and Time Courses of Fruquintinib in the FRESCO Trial
Venue: The 13th International Conference of the Asian Clinical Oncology Society in Chiang Mai, Thailand Abstract #: ABS093 Authors: Jin Li, Shukui Qin, Yuxian Bai, Yanhong Deng, Lei Yang, Zhendong Chen, Haijun Zhong, Rui-hua Xu, Hongming Pan,
閱讀更多
演示文稿, 科學出版物 | 2018-02-20

ICTO2018: Phase Ib of Savolitinib and Durvalumab in Renal Cell Carcinoma (CALYPSO)
A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Savolitinib in Patients with Metastatic Renal Cell Carcinoma S Vari1, B Szabados1, A GomezdeLiano1, K Mousa2, L Rammazzo2, A Prendergast2, T Powles1 1 Barts Health NHS Trust, Barts Can
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2018-02-13

和黃醫藥完成呋喹替尼以非小細胞肺癌為適應症的III期臨床試驗的患者入組工作，共招募527名患者
2018 年2 月13 日：和黃醫藥今日宣布呋喹替尼（HMPL-013）以非小細胞肺癌為適應症的III 期臨床試驗“FALUCA” 順利完成患者入組工作。呋喹替尼是一種高選擇性強效口服血管內皮生長因子受
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 監管通知 | 2018-02-05

Chi-Med to Announce 2017 Final Results
London: Monday, February 5, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its final results for the year ended December 31, 2017 on Monday, March 12, 2018 at 7:00 am Greenwich Mean Time (GMT). An analy
閱讀更多
公告及新聞稿, 監管通知 | 2017-12-29

Total Voting Rights
London: Friday, December 29, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 29, 2017, the issued share capital of Chi-Med consisted of 66,447,037 ordin
閱讀更多
公告及新聞稿, 監管通知 | 2017-12-29

Blocklisting Six Monthly Return
London: Friday, December 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: H
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-12-15

和黃醫藥在美國啟動呋喹替尼臨床試驗
2017年12 月15日：和黃醫藥今日宣佈在美國啟動呋喹替尼I期橋接臨床試驗。呋喹替尼是一種高選擇性強效口服血管內皮生長因子受體（VEGFR）1,2及3的抑製劑。呋喹替尼在中國以結直腸癌、肺
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 監管通知 | 2017-11-01

TR-1: Notification of major interest in shares
公告及新聞稿, 監管通知 | 2017-11-01

TR-1: Notification of major interest in shares
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-10-31

和黃醫藥啟動呋喹替尼以二線胃癌為適應症的III期臨床研究FRUTIGA
2017年10月31日：和黃醫藥今日宣佈在中國啟動呋喹替尼聯合紫杉醇（泰素® ）以晚期胃癌或胃食管結合部（GEJ）腺癌為適應症的關鍵性III期臨床研究，這項研究被命名為FRUTIGA 。呋喹替尼是
閱讀更多
下載新聞稿 (PDF)
12345
6
7891011121314